NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
NRX Pharmaceuticals, Inc. (NRXP)
Company Research
Source: Yahoo! Finance
Research and Development Expense: Decreased by approximately $2.4 million to $3.8 million from $6.2 million year-over-year. General and Administrative Expense: Decreased by approximately $0.4 million to $13.1 million from $13.5 million year-over-year. Cash and Cash Equivalents: Approximately $7.8 million as of December 31, 2025. Warning! GuruFocus has detected 4 Warning Signs with NRXP. Is NRXP fairly valued? Test your thesis with our free DCF calculator. Release Date: March 24, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points NRX Pharmaceuticals Inc ( NASDAQ:NRXP ) anticipates drug approval for KETAFREE over the summer and potential approval for NRX-100 within the year. The company has demonstrated EBITDA positive revenue growth through its HOPE Therapeutics clinics. NRX Pharmaceuticals Inc ( NASDAQ:NRXP ) has eliminated all convertible debt from its balance sheet and ended the year with $7.8
Show less
Read more
Impact Snapshot
Event Time:
NRXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXP alerts
High impacting NRX Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NRXP
News
- InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress [TheStreet.com]TheStreet.com
- NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.MarketBeat
- NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by BTIG Research. They now have a $25.00 price target on the stock.MarketBeat
- NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- NRx Pharmaceuticals GAAP EPS of -$1.34, revenue of $1.23M [Seeking Alpha]Seeking Alpha
NRXP
Earnings
- 11/14/25 - Miss
NRXP
Sec Filings
- 3/24/26 - Form 8-K
- 3/23/26 - Form 10-K
- 2/24/26 - Form DEFA14A
- NRXP's page on the SEC website